Steps forward in regulatory pathways for acute and chronic heart failure

European Journal of Heart Failure

Volumn 17, Issue 1, 2015, Pages 3-8

  Pani, Luca ^a   Pecorelli, Sergio ^a   Rosano, Giuseppe ^a,b,c   Anker, Stefan D ^d   Peracino, Andrea ^e,f   Fregonese, Laura ^g   Prasad, Krishna ^h,i   Rasi, Guido ^g,j  

^a ITALIAN MEDICINES AGENCY   (Italy)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c IRCCS SAN RAFFAELE PISANA   (Italy)

^d UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^e Fondazione Giovanni Lorenzini Medical Science Foundation   (Italy)

^f Fondazione Giovanni Lorenzini Medical Science Foundation   (United States)

^g EUROPEAN MEDICINES AGENCY   (United Kingdom)

^h MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

ⁱ ST THOMAS HOSPITAL   (United Kingdom)

^j UNIVERSITY OF ROME TOR VERGATA   (Italy)

more..

Author keywords

Clinical trial design; Health technology assessment; Heart failure; Regulatory science

Indexed keywords

ACUTE HEART FAILURE; CARDIAC PATIENT; CONSENSUS; EVALUATION STUDY; HEALTH SERVICE; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; THERAPY; WELLBEING; ACUTE DISEASE; CHRONIC DISEASE; COST BENEFIT ANALYSIS; DRUG CONTROL; DRUG DEVELOPMENT; ECONOMICS; HEART FAILURE; NEEDS ASSESSMENT; OUTCOME ASSESSMENT; PATIENT CARE PLANNING; TREATMENT OUTCOME;

CARDIOVASCULAR AGENT;

ACUTE DISEASE; CARDIOVASCULAR AGENTS; CHRONIC DISEASE; COST-BENEFIT ANALYSIS; DRUG AND NARCOTIC CONTROL; DRUG DISCOVERY; HEART FAILURE; HUMANS; NEEDS ASSESSMENT; PATIENT CARE PLANNING; PATIENT OUTCOME ASSESSMENT; TREATMENT OUTCOME;

EID: 84921341104     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.209     Document Type: Review

References (19)

1. Gheorghiade M, Zannad F, Sopko G, Klein L, Pĩa IL, Konstam MA, Massie BM, Roland E, Targum S, Collins SP, Filippatos G, Tavazzi L, for the International Working Group on Acute Heart Failure Syndromes. Acute heart failure syndromes: Current state and framework for future research. Circulation 2005;112: 3958-3968.
2. Tamargo J, López-Sendón J. Novel therapeutic targets for the treatment of heart failure. Nat Rev Drug Discov 2011;10:536-555.
3. Braunschweig F, Cowie MR, Auricchio A. What are the costs of heart failure? Europace 2011;13:ii13-ii17.
4. Vaduganathan M, Butler J, Fonarow GC, Gheorghiade M. Progress or lack of progress in hospitalized heart failure. Expert Rev Cardiovasc Ther 2013;11:1079-1083.
5. Note for Guidance on Clinical Investigation of Medicinal Products for the Treatment of Cardiac Failure. Addendum on Acute Cardiac Failure (CPMP/EWP/ 2986/03). http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003338.pdf (July 29, 2004).
6. Concept paper on the need for revision of note for guidance on clinical investigation of medicinal products for the treatment of cardiac failure (CPMP/EWP/235/95). EMA/CHMP/87576/2013, Committee for Medicinal Products for Human Use (CHMP). http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2013/03/WC500139480.pdf (11 February 2013).
7. O'Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, Heizer GM, Komajda M, Massie BM, McMurray JJV, Nieminen MS, Reist CJ, Rouleau JL, Swedberg K, Adams KF Jr, Anker SD, Atar D, Battler A, Botero R, Bohidar NR, Butler J, Clausell N, Corbalán R, Costanzo MR, Dahlstrom U, Deckelbaum LI, Diaz R, Dunlap ME, Ezekowitz JA, Feldman D, Felker M, Fonarow GC, Gennevois D, Gottlieb SS, Hill JA, Hollander JE, Howlett JG, Hudson P, Kociol RD, Krum H, Laucevicius A, Levy WC, Méndez GF, Metra M, Mittal S, Oh B-H, Pereira NL, Ponikowski P, Tang WHW, Tanomsup S, Teerlink JR, Triposkiadis F, Troughton RW, Voors AA, Whellan DJ, Zannad F, Califf RM. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011;365:32-43.
8. Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF Jr, Dorobantu MI, Grinfeld LR, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin TM, Metra M, RELAXin in Acute Heart Failure (RELAX-AHF) Investigators. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): A randomised, placebo-controlled trial. Lancet 2013;381:29-39.
9. Dharmarajan K, Hsieh AF, Lin Z, Bueno H, Ross JS, Horwitz LI, Barreto-Filho JA, Kim N, Bernheim SM, Suter LG, Drye EE, Krumholz HM. Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. JAMA 2013;309:355-363.
10. Hersh AM, Masoudi FA, Allen LA. Post-discharge environment following heart failure hospitalization: Expanding the view of hospital readmission. J Am Heart Assoc 2013;2:e000116.
11. Joynt KE, Jha AK. Thirty-day readmissions - truth and consequences. N Engl J Med 2012;366:1366-1369.
12. van Kimmenade RR, Januzzi JL. Emerging biomarkers in heart failure. Clin Chem 2012;58:127-138.
13. Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MS, Go AS, Harrell FE Jr, Hong Y, Howard BV, Howard VJ, Hsue PY, Kramer CM, McConnell JP, Normand SL, O'Donnell CJ, Smith SC Jr, Wilson PW. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 2009;119:2408-2416.
14. de Lemos JA, McGuire DK. Biomarkers in Clinical Trials: Can We Move From Fortune Telling to Disease Profiling? Circulation 2011;124: 663-665.
15. Porter M. What is value in health care? NEJM 2010;363:2477-2481.
16. Regnstrom J, Koenig F, Aronsson B, Reimer T, Svendsen K, Tsigkos S, Flamion B, Eichler H-G, Vamvakas S. Factors associated with success of market authorisation applications for pharmaceutical drugs submitted to the European Medicines Agency. Eur J Clin Pharmacol 2010;66:39-48.
17. McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GYH, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail 2012;14:803-869.
18. Maliepaard M, Nofzige C, Papaluca M, Zineh I, Uyama Y, Prasad K, Grimstein C, Pacanowski M, Ehmann F, Dossena S, Paulmichl M. Pharmacogenetics in the evaluation of new drugs: a multiregional regulatory perspective. Nat Rev Drug Discov 2013;12:103-115.
19. Butler J, Fonarow GC, Gheorghiade M. Strategies and opportunities for drug development in heart failure. JAMA 2013;309:1593-1594.